Omeros (OMER) Other Accumulated Expenses (2011 - 2026)
Omeros (OMER) posted Other Accumulated Expenses of $617000.0 for Q1 2026, up 63.23% sequentially from $378000.0 in Q4 2025, and up 10.18% YoY from $560000.0 in Q1 2025.
Analysis
Omeros (OMER) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Omeros has reported Other Accumulated Expenses for 12 years, with the latest figure at $617000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 10.18% year-over-year to $617000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $617000.0 (up 10.18% YoY) and the FY2025 annual result came in at $378000.0, up 92.86% from the prior year.
- Other Accumulated Expenses rose to $617000.0 in Q1 2026 per OMER's latest filing, from $378000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $30.6 million in Q4 2022 and troughed at $196000.0 in Q4 2024.
- A 5-year average of $7.0 million and a median of $674000.0 in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses sank 98.97% in 2023, then surged 4158.17% in 2024.
- Over 5 years, Other Accumulated Expenses stood at $30.6 million in 2022, then tumbled by 98.97% to $316000.0 in 2023, then plunged by 37.97% to $196000.0 in 2024, then surged by 92.86% to $378000.0 in 2025, then jumped by 63.23% to $617000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $617000.0, $378000.0, and $272000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 328,000.00 |
| Mar 31, 2026 | 617,000.00 |
| Dec 31, 2025 | 378,000.00 |
| Sep 30, 2025 | 272,000.00 |
| Jun 30, 2025 | 335,000.00 |
| Mar 31, 2025 | 560,000.00 |
| Dec 31, 2024 | 196,000.00 |
| Sep 30, 2024 | 23.25 Mn |
| Jun 30, 2024 | 27.97 Mn |
| Mar 31, 2024 | 28.40 Mn |
| Dec 31, 2023 | 316,000.00 |
| Sep 30, 2023 | 858,000.00 |
| Jun 30, 2023 | 847,000.00 |
| Mar 31, 2023 | 667,000.00 |
| Dec 31, 2022 | 30.55 Mn |
| Sep 30, 2022 | 674,000.00 |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 1.41 Mn |
| Dec 31, 2021 | 1.68 Mn |
| Sep 30, 2021 | 746,000.00 |